FUTUGEMET

Functional tumour genomics using metabolomic profiling

Coordinatore	CANCER RESEARCH UK    more  Organization address address: ST JOHN STREET 407 ANGEL BUILDING city: LONDON postcode: EC1V 4AD contact info Titolo: Dr. Nome: Emma Cognome: Ryley Email: send email Telefono: +44 1223 404262 Fax: +44 1223 404199
Nazionalità Coordinatore	United Kingdom [UK]
Totale costo	180˙783 €
EC contributo	180˙783 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-IEF-2008
Funding Scheme	MC-IEF
Anno di inizio	2009
Periodo (anno-mese-giorno)	2009-05-01   -   2011-04-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	CANCER RESEARCH UK  Organization address address: ST JOHN STREET 407 ANGEL BUILDING city: LONDON postcode: EC1V 4AD contact info Titolo: Dr. Nome: Emma Cognome: Ryley Email: send email Telefono: +44 1223 404262 Fax: +44 1223 404199	UK (LONDON)	coordinator	180˙783.75

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Metabolite profiling, as demonstrated by the host laboratory, has the power to discriminate single gene alterations and to identify metabolite biomarkers that potentially can function as surrogates for the genetic event. In addition they have shown that pattern recognition within NMR-derived metabolome profiles from gene deletion mutants can be used as a functional genomics tool to confirm the identity of modules or co-sets predicted by genome-scale metabolic models, demonstrating how metabolomic data can be used to understand the structure of metabolic networks, relating the metabolome to the genome. The aim of this project is to define the metabolic profiles associated with the expression of specific genes in tumour cells. This will allow us to define the metabolic network structure in tumour cells (and how it is related to expression of different oncogenes and tumour suppressor genes), and to identify metabolites that are correlated with common genetic changes in cancer cells. This should allow us to design new molecular imaging methods for detecting tumours and their response to treatment. Moreover, the proposed work will also allow us to understand the effects of specific drugs, by allowing us to monitor the modulation of the activity of specific drug targets and also by identifying off-target drug effects.'